Translational Development Acquisition (TDACU) Shares Outstanding (Diluted Average) (2023 - 2026)

Translational Development Acquisition has reported Shares Outstanding (Diluted Average) for 4 years, with the latest figure at $4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) changed 0.0% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (changed 0.0% YoY), and the FY2025 full-year result was $4.7 million, changed 0.0% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $4.7 million, roughly flat from $4.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $4.7 million in Q4 2024, with the low at $4.0 million in Q4 2023.
• Historically, Shares Outstanding (Diluted Average) has averaged $4.5 million across 4 years, with a median of $4.7 million in 2024.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Diluted Average) climbed 15.0% — and 2025, when it changed 0.0%.
• Translational Development Acquisition's Shares Outstanding (Diluted Average) stood at $4.0 million in 2023, then grew by 15.0% to $4.7 million in 2024, then changed by 0.0% to $4.7 million in 2025, then changed by 0.0% to $4.7 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $4.7 million (Q1 2026), $4.7 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.